PMID- 17691997
OWN - NLM
STAT- MEDLINE
DCOM- 20070830
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 13
IP  - 22
DP  - 2007
TI  - Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
PG  - 2237-47
AB  - Cyclo-oxygenase (COX)-2 selective inhibitors (coxibs) were designed to reduce the 
      incidence of gastrointestinal (GI) adverse events (AEs) which occur with 
      non-selective NSAIDs (ns-NSAIDs). Etoricoxib and lumiracoxib are regarded as 
      second generation coxibs because of their higher COX-2 selectivity. There are 
      three published pooled analyses relating to the GI tolerability of etoricoxib 
      (60-120 mg/day) and lumiracoxib (200-400 mg/day) which used individual patient's 
      data from studies sponsored by the manufacturers. We also reviewed new clinical 
      trials published after the pooled analyses, to determine the global GI safety 
      profiles of etoricoxib and lumiracoxib. We included discontinuations due to GI 
      events, endoscopic ulcers, symptomatic ulcers, and ulcer complications. Current 
      evidence suggests that etoricoxib and lumiracoxib have significantly more 
      favorable GI profiles than ns-NSAIDs, and are similar to first generation coxibs 
      with respect to GI safety. The most clinically important benefit of the coxibs is 
      seen in the reduced rate of symptomatic ulcer and ulcer complications, which are 
      still common in chronic NSAIDs users especially in high risk patients. In the 
      largest GI outcome study of any coxib, TARGET, involving more than 18,000 
      patients, lumiracoxib was associated with a 79% reduction in ulcer complications 
      in patients not taking aspirin. The differences between etoricoxib or lumiracoxib 
      and ns-NSAIDs in relation to ulcer complications are apparent early during 
      treatment and remain constant over time during the course of treatment; 
      therefore, benefit of etoricoxib and lumiracoxib can be seen in patients with 
      high GI ulcer complication risk who require NSAIDs from the beginning of use to 
      throughout the prescription duration.
FAU - Yuan, Yuhong
AU  - Yuan Y
AD  - Division of Gastroenterology, Department of Medicine, McMaster University Health 
      Science Centre, Hamilton, Canada.
FAU - Hunt, Richard H
AU  - Hunt RH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Sulfones)
RN  - 144O8QL0L1 (Diclofenac)
RN  - V91T9204HU (lumiracoxib)
RN  - WRX4NFY03R (Etoricoxib)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Cyclooxygenase 2 Inhibitors/*adverse effects
MH  - Diclofenac/adverse effects/*analogs & derivatives
MH  - Drug Interactions
MH  - Endoscopy, Gastrointestinal
MH  - Etoricoxib
MH  - Humans
MH  - *Occult Blood
MH  - Patient Selection
MH  - Peptic Ulcer/*chemically induced/complications/pathology
MH  - Peptic Ulcer Hemorrhage/*etiology/pathology
MH  - Pyridines/*adverse effects
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sulfones/*adverse effects
RF  - 84
EDAT- 2007/08/21 09:00
MHDA- 2007/08/31 09:00
CRDT- 2007/08/21 09:00
PHST- 2007/08/21 09:00 [pubmed]
PHST- 2007/08/31 09:00 [medline]
PHST- 2007/08/21 09:00 [entrez]
AID - 10.2174/138161207781368792 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2007;13(22):2237-47. doi: 10.2174/138161207781368792.